HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Labeling Based On Consumer Comprehension Data Stressed By McClellan

This article was originally published in The Tan Sheet

Executive Summary

Empirical data on consumer comprehension of food and drug labeling would play a prominent role in FDA rulemaking if the Senate confirms White House economic advisor Mark McClellan, MD/PhD, as the agency's new commissioner

You may also be interested in...



FDA Consumer Health Information Task Force To Be Chaired By Crawford

A new FDA task force will propose a research agenda focused on determining how science-based nutrition information is best articulated to consumers, Commissioner Mark McClellan, MD/PhD, announced Dec. 18

FDA Commissioner McClellan

White House health and economic advisor Mark McClellan, MD/PhD, unanimously confirmed by Senate Oct. 17 after Health Committee member Jeff Bingaman (D-N.M.) lifted hold on nomination (1"The Tan Sheet" Oct. 14, 2002, p. 7). Confirmation comes 21 months after former Commissioner Jane Henney, MD, left office. Although no swearing-in date had been set as of Oct. 18, FDA's Science Board meeting in Rockville, Md. Oct. 25 could mark his first public appearance as commissioner. Meeting agenda lists introductory remarks to be given by McClellan "pending confirmation." Meeting will include discussion of CFSAN counterterrorism efforts, CDER's drug GMP initiative...

Dietary Supplement GMPs Could Lean Toward Drug Model, Troy Hints

FDA's proposed rule on dietary supplement Good Manufacturing Practices could more closely follow the pharmaceutical GMPs model than would be preferred by the supplement industry

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS130887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel